What's in tirzepatide — and how does each ingredient work?

What the active molecule actually is

Tirzepatide is a 39-amino-acid peptide (a short chain of protein building blocks) synthesised in a laboratory to mimic and surpass the action of two natural gut hormones. If you would like a thorough grounding in what tirzepatide is and the science behind its design, our dedicated page walks through the chemistry and mechanism in plain language. The molecule was designed by Eli Lilly's chemists to bind GIP receptors and GLP-1 receptors with roughly equal affinity, something neither hormone manages on its own at the concentrations the body naturally produces.

The backbone of the molecule is derived from the sequence of native GIP, but it carries a fatty-acid chain attached via a linker. That modification does two things: it allows the molecule to bind albumin (a protein abundant in blood), which slows its breakdown and makes once-weekly dosing possible; and it gives the molecule access to GLP-1 receptors, which the native GIP molecule cannot activate well. The result is a single compound that speaks to both receptor types at the same time.

This dual action is what distinguishes tirzepatide from the GLP-1-only medicines you may have read about. According to NICE's technology appraisal TA1026, the committee noted that indirect comparisons and the SURMOUNT-5 head-to-head trial both favoured tirzepatide over semaglutide 2.4 mg for average weight reduction, a finding that likely reflects the additive effect of engaging two separate appetite-regulating pathways rather than one. If you want more background on what tirzepatide is and how it works, our dedicated page covers the science behind the molecule in detail. You can also visit our page on what tirzepatide is prescribed for to read about its licensed indications.

The inactive ingredients and why they matter

Alongside the active peptide, each Mounjaro KwikPen solution contains a small number of pharmaceutical excipients. These are ingredients that carry no therapeutic effect of their own but are essential for keeping the active molecule stable, sterile and at the right pH for subcutaneous injection. Typical excipients in injectable peptide medicines of this class include a buffer (to maintain pH), a tonicity agent (so the fluid behaves appropriately under the skin), and a preservative or stabiliser.

For the exact, authoritative list of excipients (including any that may be relevant if you have a known allergy) the definitive source is the Mounjaro Summary of Product Characteristics on the electronic Medicines Compendium (eMC). The SmPC lists every ingredient by name and quantity. It is worth checking if you have hypersensitivities, because excipients in injectable medicines occasionally contain trace components relevant to certain allergies; your prescriber can advise.

The solution itself arrives in a pre-filled, multi-dose KwikPen. Each pen contains four weekly doses at the stated strength. The device locks after use and the needle is attached fresh for each injection. When your treatment is dispatched by our GPhC-registered pharmacy, the pen travels refrigerated inside a plain, unbranded box with DPD tracking so you know exactly when to be home, because these pens need to go straight into the fridge door.

How the ingredients produce their effects in the body

Once injected subcutaneously, tirzepatide is absorbed slowly into the bloodstream, the fatty-acid chain extending its half-life to roughly five days, which is what sustains once-weekly action. In circulation, it reaches GIP and GLP-1 receptors distributed across the pancreas, brain, gut, fat tissue and elsewhere.

Activation of GLP-1 receptors slows gastric emptying (food moves through the stomach more gradually, prolonging fullness), suppresses appetite signalling in the hypothalamus, and stimulates insulin release in a glucose-dependent way. GIP receptor activation adds complementary effects on fat metabolism and may reinforce the central appetite signals through slightly different neural pathways. The combined result, seen across the SURMOUNT-1 clinical trial involving 2,539 adults, was an average body-weight reduction of around 20–21% at the 15 mg dose over 72 weeks, figures the SURMOUNT-1 paper in the New England Journal of Medicine describes in full.

It is the interaction between these ingredients and your own physiology that a prescriber evaluates before recommending tirzepatide. For a broader look at the medicine and how it fits into weight management, our page explaining what Mounjaro is pulls together the key facts. Cost context, including how private pricing is structured, is covered separately on our guide to Mounjaro pricing in the UK.

What the ingredients do not include

A question our prescribers hear fairly regularly: does tirzepatide contain insulin, hormones derived from animals, or stimulants? The short answer is no. It is a fully synthetic peptide; no insulin, no thyroid hormone, no amphetamine-class compound. It is not a stimulant in the pharmacological sense, and it does not raise heart rate as a primary mechanism the way some older weight-loss medicines did.

It is also worth being clear about what the pen does not contain: any guarantee of a particular result. Tirzepatide works in the presence of the lifestyle changes the licence specifies, a reduced-calorie diet and increased physical activity. Some patients and clinicians also discuss smaller introductory amounts of the drug, and if you are curious about that approach, our page on what a microdose of tirzepatide involves explains the concept clearly. Our FAQs page addresses some of the common questions about starting treatment, and you can explore all available options on the weight-loss treatments overview.